Tempus AI, Inc. (TEM) Stock
TEM Key Statistics
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
CEO: Eric Lefkofsky. Company website
TEM — Frequently Asked Questions
What is the TEM stock price today?
Tempus AI, Inc. (TEM) trades at $77.84, down 3.14% on the day, as of Sep 20, 2026 14:57 UTC.
What is Tempus AI, Inc.'s market cap?
Tempus AI, Inc. has a market capitalisation of $13.64B, calculated from the live TEM share price and shares outstanding.
What is the P/E ratio of TEM?
TEM has no meaningful price-to-earnings ratio: Tempus AI, Inc. lost $1.44 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Tempus AI, Inc. make?
Tempus AI, Inc. generated revenue of $1.43B over the trailing twelve months, which puts the stock at 9.52 times sales.
What is the 52-week range for TEM?
TEM has traded between $40.77 and $104.32 over the past 52 weeks, and the last price is 25.4% below that high.
Is Tempus AI, Inc. profitable?
No. Tempus AI, Inc. is loss-making, with a net margin of -17.77% over the trailing twelve months.
What is the analyst price target for TEM?
Wall Street analysts rate TEM Buy, with an average price target of $69.33, 10.9% below the current price.
What sector is Tempus AI, Inc. in?
Tempus AI, Inc. is classified under the Healthcare sector and the Medical - Healthcare Information Services industry, and is domiciled in US.
Who is the CEO of Tempus AI, Inc.?
Eric Lefkofsky is the chief executive of Tempus AI, Inc., which employs 3,800 people.
Where can I track TEM in real time?
QFI Terminal shows TEM with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TEM live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TEM in Terminal See plans